Skip to main content
. 2020 Sep 10;15(22):2121–2135. doi: 10.1002/cmdc.202000391

Figure 6.

Figure 6

Structures of clinical and FDA‐approved PARP inhibitors with nicotinamide/benzamide pharmacophore group shown in blue